 Janpix, Inc., a privately-held biopharmaceutical company dedicated to the discovery and development of inhibitorsdegraders of Signal Transducer Activator of Transcription STAT proteins for oncological indications, announced today the appointment of Sanford Zweifach as the Companys Executive Chairman of the Board of Directors. Mr. Zweifach brings to Janpix almost 30 years of experience in senior executive roles in the life sciences industry, with a focus in corporate partnering, business development, operations, private and public investing, and capital raising. 